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“Chemobrain” or chemotherapy induced cognitive im-
pairment (CICI) represents a new clinical entity, charac-
terized by executive dysfunction, deficit of memory and 
learning and motor function impairment after a chemo-
therapy (CT) regimen 1 2. Cancer is an age-related dis-
ease and, due to the aging population, is going to result 
a relevant disease of the elders. With the advent of new 
surgical and chemotherapy options, oncogeriatric pa-
tients will turn to be long-term survivors and chemobrain 
will represent an issue of growing geriatric interest.
To a greater extent, CICI may be regarded as a drug 
side effect that may be a short-term event or lasting 
up to 10 years after chemotherapy cessation 3 4, with 
gradual cognitive decline and great variability among 
patients.
Several studies have focused on the effect of cyclophos-
phamide and doxorubicin in breast cancer patients 5 6. 
A recent metanalysis  7 has revealed that cancer pa-
tients treated with CT may develop verbal memory and 
executive function impairment that interfere with daily 
living and quality of life. Moreover, the cognitive deficit 
may last over 20 years, addressing the need for a better 
clinical identification of this issue 8.
The impaired neuropsychological findings correlate with 
neuro-structural changes. Indeed, neuro-structural brain 
radiology and functional imaging have recently demon-
strated an association between chemobrain and lower 
activation of dorso-lateral, caudal frontex cortex, and 
reduced glucose metabolism in frontal lobes after CT 9 10. 
A series of different chemotherapy compounds have 
been implicated in the pathogenesis of chemobrain, 
including platinum compounds, proteasome inhibitors, 
tyrosine kinase inhibitors and interferon alpha. 
The main mechanisms of chemotherapy induced 
cognitive changes include direct neurotoxicity, genetic 
predisposition, immune dysregulation, shortened tel-
omeres, inflammation and oxidative stress. 
Recently, an interesting review of Gaman et al.  11, 
pointed out the state of the art and the new horizons 
of chemobrain with respect to the aging process, the 
brain aging and the underlying oxidative stress. 
Both chemobrain and brain aging seem to be associ-
ated with reactive oxygen species (ROS) production and 
accelerated oxidative stress. CICI may be directly due 
to the ROS burst generated during chemotherapy. The 
most studied in vitro and in vivo murine models include 
doxorubicin (anthracycline) 12 13. This common CT agent 
is considered to increase superoxide free radicals’ pro-
duction with oxidation of ApoA1 and the promotion of 
TNF alpha synthesis. This last cytokine mediator inter-
acts with its receptor on the blood brain barrier (BBB) 
surface and reaches the brain parenchyma, generating 
neuronal apoptosis and death, mitochondria mutation 
(with increased p53) and increased lipid peroxidation, 
ultimately responsible for chemobrain occurrence (Fig 1). 
In particular, brain lipid peroxidation (leads to toxic 
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compounds such as aldehyde (4-hydroxinonenal) 
with increased neuronal death. In parallel, reduced 
glutathione levels and increased glutathione-S – trans-
ferase were also detected in brain after CT.
Further understanding of the mechanisms of different 
CT compounds is accumulating as well. Carmustine is 
associated with a significant increase of oxidative stress 
(malondialdehyde) and overexpression of caspase  3, 
activation of c-jun N- terminal kinase (JNK) and ERK 
pathways  14. Interestingly, carmustine mediates the 
production of metallothionein in rat models that has an 
anti-oxidant protective effect.
Methotrexate is associated with increased levels of 
TNF alpha, increased lipoperoxidation, increased HP70 
protein and reduced glutathione levels 15. Interestingly, 
methotrexate was found to decrease in vitro stem cells 
in hippocampus, that could count for the onset of cog-
nitive impairment.
Cyclophosphamide is associated with increased levels of 
lipid peroxidation, TNF alpha and interleukin-6, increased 
production of COX2, I NOS, p38 -MAPK and NfkB 16. 
However, how CT oxidative stress mediated brain 
changes may be linked to brain aging has not yet been 
answered.
Thus, CT compounds seem to mediate ROS release 
by increasing plasma cytokines, capable of penetrating 
the BBB.
Normal brain aging is characterized by widespread but 
not homogeneous neuronal death, especially in frontal 
lobes and hippocampus, with reduction of grey and 
white matter. White matter is more vulnerable to oxida-
tive stress and then, both chemobrain and brain aging 
could start from the same brain regions. During brain 
aging, neuronal remodelling and integrity result from 
the coping with perturbation of different metabolic and 
molecular signalling, causing endothelial damage and 
neuronal and cellular death 17. 
Oxidative stress and vascular injury are also the biologi-
cal background for cerebral atherosclerosis and small 
vessel disease that may be involved in both vascular 
and Alzheimer’s type dementia. 
To a greater extent, the aging process is itself a potent 
epigenetic modulator of brain, by increasing ROS gen-
eration and mitochondrial dysfunction with proteins and 
lipid and inflammatory damage, altered cell signalling 
pathways, apoptosis and altered gene expression  18. 
Indeed, the Harman’s hypothesis of free radicals claims 
for the accumulation of oxidative damage to lipids, 
Figure 1. The multifactorial origin of chemobrain and potential neurodegenerative trajectories on the basis of the aging brain. 
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protein, DNA. Complementary to it, there is the mito-
chondrial theory of aging that mainly affect insulin/IGF-1 
signalling, target for rapamycin (mTOR).
Interestingly, increasing in vivo evidence underlined that 
aging may promote brain alterations of TNF alpha in a 
similar way to chemotherapeutic compounds. 
The interplay between the aging brain, chemobrain and 
dementia represents a challenge for geriatricians and 
bio gerontologists in the near future.
Research should consider cancer and chemotherapy, 
as potential vulnerability factors, when assessing cogni-
tive functioning and its trajectories in eldelry patients. 
Chemobrain and CT should be framed in a larger 
conceptual framework; CT associated mechanisms 
mediating reversible or permanent dysregulation of an 
aging brain could be disentangled and integrated in the 
different trajectories of cognitive performance in elders. 
In addition, the psychological stress after the diagnosis 
of cancer, the psychosocial resources and the comor-
bidity burden may represent further moderator of the 
cognitive performance.
Considering it as a starting point, more explanatory 
models are needed to support preclinical evidence and 
to develop effective clinical evidence.
Chemobrain is expected to rely on different patho-
genetic mechanisms; chemotherapy regimens are 
responsible for direct neurotoxic insult mediated by 
oxidative stress and neuroinflammation. All these 
mechanisms are responsible for increased neuronal 
dysfunction and death. There is great heterogeneity 
among different chemotropic compounds according 
to their blood brain barrier permeability and penetra-
tion; these different physio pathological pathways may 
count for different brain burden and impact on cogni-
tive performance. 
The aging brain may be temporary perturbed by a 
CT insult, showing cognitive decline after one- three 
months of therapy. However these deficits had gen-
erally resolved at one year follow up or persisting as 
subjective memory or cognitive impairment. 
By contrast, a frail brain, that may be defined as a re-
duced functional reserve organ with poor homeosten-
otic adaptation, could be heavily perturbed by a CT 
stressor. In turn, CT may initiate a neurodegenerative 
trajectory with a mild cognitive impairment that may 
ultimately end into a dementia conversion.
Not least, the inverse relationship between cancer and 
dementia of Alzheimer’s type represents a further area 
of inquiry that deserves clinical evidence, especially in 
the older populations. 
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